LIBI-Diagnostics
Cancer Diagnostic Test
StartupLIBI-Diagnostics is a Haifa-based startup in the Health Tech & Life Sciences sector, established in 2020. Cancer Diagnostic Test. LIBI-Diagnostics was founded by David Risin and Dr. Ayelet Ben Barak. Key investors include Headstart. The company has 1-10 employees. Core technologies: Biologicals, Genes.
The company follows a B2B business model. Product stage: R&D.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQHaifa
- DistrictNorth District
- Last Round$100K
- HeadstartLead
David RisinCo-Founder & CEO
Dr. Ayelet Ben BarakCo-founder & CMO
What does LIBI-Diagnostics do?
LIBI Diagnostics is a gene-biomarker start-up for the early detection of cancer, powered by next-generation bio-liquid tests. Using state-of-the-art Next-Generation Sequencing (NGS) technology, LIBI-Diagnostics customizing tests for each patient by detecting alterations of Aurora Kinase A in blood and/or voided urine samples compared to the genomic expression data in the primary tumor. Libi-Diagnostics provides a practical and effective answer to the the inefficiency of periodic imaging tests. LIBI diagnoses recurrent cancerous development in an early stage with only few cells and provides sufficient information to neutralize that early development. In this way, it is possible to spare the patient aggressive treatments, unnecessary suffering and maintain his good chances of survival.
Who founded LIBI-Diagnostics?
LIBI-Diagnostics was founded in 2020 by David Risin (Co-Founder & CEO), Dr. Ayelet Ben Barak (Co-founder & CMO).
What sector is LIBI-Diagnostics in?
LIBI-Diagnostics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Healthcare, Patients.
Where is LIBI-Diagnostics located?
LIBI-Diagnostics is based in Derekh Yafo 51, Haifa, Israel, North District.